NCT05770570 Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
| NCT ID | NCT05770570 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Overweight |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,785 participants |
| Start Date | 2022-12-22 |
| Primary Completion | 2027-02-26 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 1,785 participants in total. It began in 2022-12-22 with a primary completion date of 2027-02-26.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The researchers will conduct 'Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity)', which also utilizes MOST, and the same 4 obesity intervention components as in SANOS, but targets the overweight/obesity crisis in another at-risk, low socioeconomic status (SES) population, taxi and for-hire vehicle (FHV) drivers (Lyft, Uber, etc.). ROADMAP also utilizes an effectiveness- implementation hybrid type 1 design. Hybrid trials, which blend effectiveness and implementation studies, can lead to more rapid translational uptake and more effective implementation. Taxi and FHV drivers are a growing, multilingual, hard-to-reach, predominantly immigrant and minority essential worker population. There are over 750,000 licensed taxi and FHV drivers in in the U.S. and over 185,000 in New York City (NYC). They have higher rates of overweight/obese range body mass index (BMI) than New Yorkers in general (77% vs 56%) and have high rates of elevated waist circumference, sedentary behavior, poor diets, and health care services underutilization. ROADmAP will test 4 evidence- and theory-based (Social Cognitive Theory \[SCT\]) behavior change intervention components. We will use MOST to identify which of the 4 components contribute most significantly and cost-effectively to weight loss among NYC drivers recruited at workplace health fairs (HFs) and virtually. Objectives are to apply MOST to design an optimized version of a scalable, lifestyle intervention for taxi/FHV drivers, and then to conduct a mixed methods multistakeholder process evaluation to facilitate widespread intervention implementation.
Eligibility Criteria
Inclusion Criteria: For COMIDA participants only: * Self-Identifies as Mexican American or Mexican * Seeking services at the VDS of the Mexican Consulate * Prefers to speak in Spanish * All adults at least 18 years of age * Screens as obese (an adult who has a Body Mass Index (BMI) 30 or higher) or overweight (an adult who has a BMI between 25 - 29.9) * Agrees to be audio recorded For SANOS focus group participants only: * Self-identifies as Hispanic/Latino; * Seeking services at VDS or VDS Mobile; * Prefers to speak in Spanish; * At least 18 years of age; * Screens as obese (BMI ≥ 30 kg/m\^2) or overweight (BMI of 25 - 29.9 kg/m\^2); * Agrees to be audio recorded For SANOS RCT participants only: * Self-identifies as Hispanic/Latino; * Seeking services at VDS or VDS Mobile; * Prefers to speak in Spanish; * At least 18 years of age; * Screens as obese (BMI ≥ 30 kg/m\^2) or overweight (BMI of 25 - 29.9 kg/m\^2); * Owns a cell phone capable of receiving text messages; * Agrees to be audio recorded For Family COMIDA participants only: * Self-Identifies as Hispanic/Latino * Seeking services at the VDS (or has used VDS services in the past) of the Mexican - Consulate or VDS Mobile * Prefers to speak in Spanish * At least 18 years of age * Has at least one child under age 18 living in the same household * Owns a cell phone capable of receiving text messages * Willing to receive text messages (3 texts per week for 3 months) * Owns an internet connected device (eg, cell phone, tablet, etc) capable of conducting teleconference calls (eg, Zoom) For ROADmAP RCT participants only: * At least 21 years of age * Full-time (drives at least 35 hours per week) licensed taxi/FHV driver * Driver for at least 6 months * Seeking Health Fairs (or has used Health Fairs services in the past) * Speaks English, French, Bengali, or Spanish * Screens a as obese (BMI ≥ 30 kg/m2 \[≥25 kg/m2 for South Asians\]) or overweight (BMI of 25 - 29.9 kg/m2 s \[23- 24.9 kg/m2 for South Asians\]) * (BMI cut-offs are lower for South Asians, per WHO and American Diabetes Association recommendations) * Owns a cell phone capable of receiving text messages * Agrees to be audio-recorded For ROADmAP Phase 2 participants only: * At least 21 years of age * Driver who participated in ROADmAP RCT or manager at a taxi garage, Uber, Lyft or driver serving/union/organization * Agrees to be audio-recorded Exclusion Criteria: For COMIDA participants only: * Will not be in the NYC area for the study duration (3-4 months) Is pregnant or might be pregnant * Lactating women * Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (Individuals with diabetes, lactose intolerance, and high blood pressure MAY still participate in the study) * Has dietary restrictions (i.e. liquid diet) * Does not have a phone that accepts text messages or unwilling to accept text messages * Presence of a serious psychiatric or cognitive impairment likely to preclude meaningful informed consent and adherence to the protocol per the consenting professional"s judgment * Has another family member already enrolled in COMIDA (as determined by patient report) For SANOS focus group participants only: * Is pregnant or might be pregnant; lactating women; * Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate); * Has dietary restrictions (i.e. liquid diet); * Has a household member who has already participated (or agreed to participate); For SANOS RCT participants only: * Is pregnant or might be pregnant; lactating women; for the study duration (6 months) * Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate); restricting diet; * Currently has dietary restrictions (i.e. liquid diet); * Has a household member who has already participated (or agreed to participate); * Has already participated in the study * Will not be in the NY Metropolitan area for the study duration (6 months) Works for or with the Mexican consulate (including employment and/or collaborative or volunteer services) For Family COMIDA participants only: * Is pregnant or might be pregnant; lactating women for the study duration (3 months) * Will not be in the NY Metropolitan area for the study duration (3 months) Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (Individuals with diabetes, lactose intolerance, and high blood pressure MAY still participate in the study) * Has dietary restrictions (i.e. liquid diet) * Has another family member who has already participated in COMIDA or SANOS * Has already participated in the study * Works for or with the Mexican consulate (including employment and/or collaborative or volunteer services) For ROADmAP RCT participants only: * Is pregnant or might be pregnant; lactating women; for the study duration (12 months) * Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate) that may restrict diet * Currently has dietary restrictions (i.e. liquid diet) * Has a household member who has already participated (or agreed to participate) * Has already participated in the study * Will not be in the NY Metropolitan area for 6 months from study enrollment * Is currently taking Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity Saxenda, Victoza, Phentermine (Adipex, Lomaira), Extended-release Phentermine/Topiramate (Qsymia), Extended-release Naltrexone/Bupropion (Contrave), Plenity, Orlistat (Xenical) or Other GLP-1 receptor agonist, or any other drug to treat obesity or there is less than 7 weeks since last dosage. * Has undergone weight loss/bariatric surgery or is planning to undergo such surgery in the next 12 months.
Contact & Investigator
Jennifer Leng, MD, MPH
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT05770570 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05770570 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05770570 currently recruiting?
Yes, NCT05770570 is actively recruiting participants. Contact the research team at lengj@mskcc.org for enrollment information.
Where is the NCT05770570 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05770570 clinical trial?
NCT05770570 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Jennifer Leng, MD, MPH at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 1,785 participants.